Zhixiang A-H Statistics | January 13th

HENGRUI PHARMA (01276): HRS-7535 Tablets Approved for Clinical Trials Targeting Hypertension with Overweight or Obesity

Zhiti AH Statistics | January 12

JPMorgan Increases Stake in Hengrui Pharma by Approx. 1.13 Million Shares at HK$74.61 per Share

JPMorgan Boosts Stake in Hengrui Pharma (01276) by Approximately 1.13 Million Shares at HK$74.61 Per Share

ZhTong AH Statistics | January 9th

Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug

BRIEF-Jiangsu Hengrui Pharmaceuticals Says Unit Got Notice From NMPA For Retlirafusp Alfa Injection

Jiangsu Hengrui Pharmaceuticals - Unit Got Notice From Nmpa China for Retlirafusp Alfa Injection

Suzhou Suncadia Biopharmaceuticals Wins NMPA Drug Approval

HENGRUI PHARMA (01276) Cumulatively Repurchased 8.8987 Million A-Shares by End of December

Zhiton AH Statistics | January 2nd

Hong Kong Stocks Movement | Hengrui Pharma (01276) Surges Over 5% in Afternoon Session as CLDN18.2 ADC Gastric Cancer Indication Included in Breakthrough Therapy List

Jiangsu Hengrui Medicine Co. Ltd. Held Extraordinary Shareholders' Meeting

Zhixintong Hong Kong Stock Short Position Statistics | December 29

HENGRUI PHARMA (600276.SH) Signs Exclusive Licensing Agreement with HANSOH PHARMA for SHR6508 Project

Hengrui Pharma to Release 2025 Annual Report on March 26, 2026; Q4 Consensus Revenue Forecasted at 32.07-36.06 Billion Yuan

Zhiton AH Statistics | December 26

Jiangsu Hengrui Pharmaceuticals (600276.SH): Injectable SHR-A1904 Included in Breakthrough Therapy List